In Lewy body diseases, multimodal biomarker integration—including myocardial 18F-dopamine PET, olfactory testing, and synuclein–tyrosine hydroxylase co-localization—can distinguish synucleinopathy-positive from -negative patients [407]. This evidence concerns the gene SNCA and synucleinopathy.